

Congress Executive Committee

President

Prof. Vittorio Pengo
Dpt of Cardiovascular Sciences
University of Padua

Vicepresident

Prof. Paolo Prandoni
Dpt of Cardiovascular Sciences
University of Padua

Members of the Local Organizing Committee

Banzato Alessandra
Bilora Franca
Bison Elisa
Bracco Alessia
Denas Gentian
Milan Marta
Padayattil Jose Seená
Pesavento Raffaele
Sarolo Lucia
Villalta Sabina
Visonà Adriana
Zanon Ezio
Zoppellaro Giacomo

www.thrombosis2018.org



European and Mediterranean League
against Thrombotic Diseases

EMLTD

Technical Secretariat



www.geyseco.es

Phone (+34) 963511632 Fax (+34) 963942558

secretariat_emltd@geyseco.es



European and Mediterranean League
Against Thrombotic Diseases

EMLTD

25th BIENNIAL INTERNATIONAL CONGRESS ON THROMBOSIS

23-26 May, 2018

**Palazzo del Casino - Venice Convention Center
Venice, Italy**

Deadline for abstract submission:

December 15, 2017

www.thrombosis2018.org





Dear Colleagues,

It is my great pleasure to invite you, on behalf of the Council of the European and Mediterranean League against Thrombotic diseases, to the 25th International Congress on Thrombosis to be held in Venice on May 2016.

As you all are aware of, thrombosis (coronary, cerebral and venous) accounted for two of three deaths in 2010 (Lancet 2012; 380:2095-128). Prevention and treatment of thromboembolic events is therefore a main issue in medicine that involves all the components of health care system. Recently, a strong boost in this field came from the introduction of new antithrombotic agents whose use is expanding with the need of more information by real-life studies. Thus, ICT is an important venue to compare clinical experiences and learn new advances in basic and pharmacological sciences.

The Scientific Programme will be primarily devoted to young scientists and physicians with 'meet the expert' sessions early in the morning. 'Pros' and 'cons' debate will also stimulate discussion with the audience. Main lectures relevant to thrombotic hot topics will be also hosted and sponsored symposia will take place as lunch sessions.

Keynote lectures will be delivered by a distinguished international faculty, while a large number of selected free communications will report new data from basic research laboratories and clinical centers around the globe.

A program committee, made of experts, has been appointed to prepare a high-quality scientific program that, we are sure, will meet all the expectations and needs of the numerous participants to the meeting.

Finally, it should be emphasized that the Congress will be held in one of the most attractive locations in the world. Venice is a unique city, which has preserved its structural integrity over the centuries; from a natural, artistic, and historical point of view it is a veritable treasure. We are confident that all these fascinating features will make ICT 2016 a wonderful and unforgettable event.

We look forward to welcoming you in Venice.

Sincerely,

Vittorio Pengo MD, FESC

MAIN TOPICS

DOACS for stroke prevention in atrial fibrillation
DOACS in patients with VTE
Duration of anticoagulation in VTE
Prevention of thrombosis
Thrombolysis and/or thrombectomy in ischemic stroke

Atrial fibrillation and stroke

- Benefit vs risk of long term anticoagulation
- To treat or not to treat CHADSVASC 1 patients
- Cardioversion and risk of stroke
- Ablation of atrial fibrillation and stroke

Atrial fibrillation: non pharmacological stroke prevention

- Left atrial appendage closure-indications, techniques, and outcomes
- Left Atrial Appendage Closure With Watchman Device: Long-Term Results
- A registry to evaluate real-world outcomes in patients with AF treated with Watchman device
- Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation

Treatment of patients with pulmonary embolism

- Risk stratification: focus on intermediate risk
- Thrombolytic therapy: when and to whom
- DOACs to every one?
- Home treatment: are we concerned?

Treatment of Chronic Thromboembolic Pulmonary Hypertension

- Residual clot and long-term complications in patients with PE
- Best practical guidelines
- European registry
- Italian experience on pulmonary endarterectomy: focus on NYHA class II patients

Basic science in thrombosis

- Contact system activation on endothelial cells
- Platelet secretory behaviour
- Endothelial progenitor cell-capture stent in myocardial infarction
- Proteomic signature of endothelial dysfunction identified in patients with acute ischemic stroke

Atherosclerosis and its complications

- Which antiplatelet therapy in minor stroke?
- Atheroma burden and morphology in women
- New perspectives on the prevention and management of peripheral artery disease
- Impact of carotid artery stenting on cognitive function

Antiplatelet treatment and its monitoring

- Aspirin: an old drug for newer indications
- The potential of the newer antiplatelet therapies
- Value of adding antiplatelet to anticoagulant drugs for prevention of CHD
- Aspirin in patients undergoing non-cardiac surgery

Thrombosis in women

- Risk of AML and stroke in women on hormonal treatment
- Preventive strategies in thrombophilic women during pregnancy
- Hormone replacement therapy: benefits and risks
- Recurrent pregnancy loss

Cancer-associated thrombosis (CAT)

- Search for occult cancer in patients with unprovoked VTE
- Role of biomarkers for assessing the risk of CAT
- DOACS for the management of CAT
- Prevention of CAT in patients undergoing chemotherapy

Management of the post-thrombotic syndrome (PTS)

- Inflammation and PTS
- Elastic stockings for prevention and treatment of PTS
- Catheter-directed thrombolysis and prevention of PTS
- The potential of the DOACS for prevention of the PTS

DEBATES

- Treatment of incidental PE in cancer patients
- Hormonal treatment in women with thrombosis
- Monitoring of the DOACs
- CUS or whole leg investigation in clinically suspected DVT
- Length of thromboprophylaxis in admitted medical patients
- Venous and arterial thrombosis: is there a link
- Anticoagulant treatment of SVT
- Patent foramen ovale and cryptogenic stroke: to close or not to close
- Duration of dual antiplatelet therapy after PCI and stenting
- VTE prophylaxis in knee arthroscopy